REG - Redx Pharma plc - Appointment of Joint Broker

Redx PharmaAnnouncement

15/03/2021 07:05

RNS Number : 1856S
  
Redx Pharma plc
  
15 March 2021
  
 

 
 
REDX PHARMA PLC
("Redx" or "the Company")
 
Appointment of Joint Broker
 
Alderley Park, 15 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that it has appointed Panmure Gordon (UK) Limited to act as Joint Broker to the Company alongside WG Partners with immediate effect. 
 
 



For further information, please contact:


















Redx Pharma Plc 


T: +44 1625 469 918




Iain Ross, Chairman
Lisa Anson, Chief Executive
James Mead, Chief Financial Officer


















SPARK Advisory Partners (Nominated Adviser)


 T: +44 203 368 3550




Matt Davis/Adam Dawes


















WG Partners LLP (Joint Broker)


T: +44 20 3705 9330




Claes Spång/Chris Lee/David Wilson


















Panmure Gordon (UK) Limited (Joint Broker)


T: +44 20 7886 2500




Rupert Dearden/Freddy Crossley/Emma Earl




























FTI Consulting


T: +44 20 3727 1000




Simon Conway/Ciara Martin








 
 







 
About Redx Pharma Plc 
 
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
 
The Company's  core capability  of converting  medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
APPDKQBBCBKDQND